Maze Therapeutics, Inc. (MAZE)
NASDAQ: MAZE · Real-Time Price · USD
25.95
-0.52 (-1.96%)
At close: Apr 28, 2026, 4:00 PM EDT
25.75
-0.20 (-0.77%)
Pre-market: Apr 29, 2026, 8:53 AM EDT

Maze Therapeutics Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22
Cash & Equivalents
189.25196.8129.1699.92
Short-Term Investments
152.67---
Cash & Short-Term Investments
341.92196.8129.1699.92
Cash Growth
73.73%574.99%-70.82%-
Other Receivables
1.5---
Receivables
1.5---
Prepaid Expenses
6.34.864.956.23
Total Current Assets
349.72201.6734.11106.15
Property, Plant & Equipment
25.1629.9234.9841.23
Long-Term Investments
18.11---
Long-Term Deferred Charges
-4.6--
Other Long-Term Assets
4.144.352.412.58
Total Assets
397.13240.5471.5149.96
Accounts Payable
1.791.942.021.59
Accrued Expenses
15.9714.19.8114.87
Current Portion of Leases
4.84.634.494.32
Total Current Liabilities
22.5620.6716.3220.78
Long-Term Debt
--20.08-
Long-Term Leases
18.512225.0527.73
Other Long-Term Liabilities
1.090.97--
Total Liabilities
42.1643.6461.4548.51
Common Stock
0.05000.02
Additional Paid-In Capital
844.3547.2421.8412.79
Retained Earnings
-489.55-358.43-395.69-295.27
Comprehensive Income & Other
0.11---
Total Common Equity
354.97-311.18-373.85-282.46
Shareholders' Equity
354.97196.910.05101.44
Total Liabilities & Equity
397.13240.5471.5149.96
Total Debt
23.3126.6349.6232.06
Net Cash (Debt)
318.61170.18-20.4767.86
Net Cash Growth
87.22%---
Net Cash Per Share
7.4162.33-8.9433.76
Filing Date Shares Outstanding
49.7143.82.322.01
Total Common Shares Outstanding
49.332.442.322.01
Working Capital
327.1618117.7985.37
Book Value Per Share
7.20-127.72-160.95-140.52
Tangible Book Value
354.97-311.18-373.85-282.46
Tangible Book Value Per Share
7.20-127.72-160.95-140.52
Machinery
17.9717.3116.4716.08
Construction In Progress
0.040.030.06-
Leasehold Improvements
5.515.455.365.33
Source: S&P Capital IQ. Standard template. Financial Sources.